Trial Profile
A Double-Blind, Placebo-Controlled, Crossover Study in Subjects With Cerebral Palsy to Evaluate the Safety and Tolerability and the Effect on Sensorimotor Function of Dalfampridine-ER
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Feb 2017
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Cerebral palsy
- Focus Adverse reactions
- Sponsors Acorda Therapeutics
- 25 Jan 2017 Results published in the Clinical Therapeutics
- 11 May 2014 New trial record
- 04 Apr 2013